A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone
Launched by ALVOGEN KOREA · Apr 1, 2016
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy male subjects age between 19 and 55 signed informed consent
- Exclusion Criteria:
- • subjects have an allergy reaction of this drug
About Alvogen Korea
Alvogen Korea is a leading pharmaceutical company dedicated to the development, manufacturing, and commercialization of high-quality generic and specialty medications. With a strong emphasis on innovation and patient-centric solutions, Alvogen Korea leverages advanced technologies and robust research capabilities to deliver a diverse portfolio of therapeutic options across various medical fields. The company is committed to enhancing healthcare access through cost-effective products while ensuring compliance with stringent regulatory standards. Alvogen Korea actively collaborates with healthcare professionals and stakeholders to drive clinical research initiatives and contribute to the advancement of global health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials